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Avian influenza viruses (AIV) are major cause of morbidity and mortality in the world. 
It is the causative agent of the most dangerous disease, called bird flu in common terms, 
among poultries. This virus belongs to the family of Orthomyxoviridae which contains 
two genera, influenza A & B and influenza C.  Although avian influenza A viruses do 
not usually infect humans, several instances of human infections and outbreaks have 
been reported. Spanish flu, the well known influenza pandemic of 1918, is thought to 
have killed more than 50 million people worldwide. Although vaccination is the primary 
strategy for the control of infection, the antiviral drugs play an important role in the 
control of illness and transmission. Two classes of antiviral drugs are recommended for 
the treatment of influenza infection. They are adamantane derivatives (amantadine and 
rimantadine) and neuraminidase inhibitors (NAIs; zanamivir and oseltamivir). The rate 
of adamantane resistance has increased significantly from below 2% to an alarming 
92.3% in recent years. Few viruses with altered susceptibility to NAIs have also been 
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isolated from the infected people. Several recent H5N1 influenza isolates recovered 
from the patients showed resistance to both classes of antiviral drugs. The increasing 
appearance of resistant strains of influenza virus and side effects of the currently 
available chemotherapeutic agents emphasises our need to identify new antiviral drugs. 
 
In order to identify novel antiviral drugs, phage display library was utilised in this study. 
They were biopanned against the purified avian influenza virus H9N2. After four rounds 
of biopanning, four unique recombinant fusion phages bearing different peptide 
sequences were isolated. Their binding specificity was confirmed by modified phage-
ELISA method. Among the four peptides, the peptide denoting the sequence NDFRSKT 
(P1) was taken into account for further analysis as it showed a high percentage of 
presence after the fourth round of panning and good inhibitory properties. 
 
The in vitro inhibitory properties of the fusion phages were proved by the ability of the 
phage molecules to stop the multiplication of the virus in MDCK cell lines whereas, the 
in ovo inhibition ability of both peptides and fusion phages were assessed using the 9 
days old embryonated chicken eggs. The antiviral molecule’s ability to inhibit the 
hemagglutination activity and neuraminidase (NA) activity were also investigated using 
conventional hemagglutination inhibition test and neuraminidase inhibition test 
respectively. They were able to inhibit the HA activity but failed to inhibit the 
neuraminidase activity completely. The antibody-phage competition assay showed that 
the peptide molecule share some common epitopes of the viral surface proteins for their 
binding site. In order to investigate the in vivo binding ability of the molecules inside a 
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cellular environment and to identify the binding domain on the viral proteins, the 
peptide and virus surface glycoproteins interaction were analysed by the yeast two-
hybrid system. The results showed that the C-terminal region of the HA protein was 
responsible for the interaction with the peptide. This was further confirmed by the co-
immunoprecipitation experiment. 
 
To understand the mechanism of the drug action, the effect of drug on the viral 
attachment and the viral entry to the host cell (MDCK cells) was studied by fluorescence 
microscopy and flow cytometry. The study revealed that the peptides prevent the 
attachment of the virus to the host cells, confirming the result of earlier 
haemagglutination inhibition experiment. Besides, it was also found that the peptides 
inhibit the early gene expression. But the peptides do not have any effect on preventing 
the entry of the virus molecules. 
 
In summary, the current study had identified a novel antiviral peptide which inhibits the 
AIV H9N2 multiplication in ovo and in vitro, by binding the HA. This peptide prevents 
the attachment of the virus to the host cells thereby preventing its internalisation and 
early protein expressions. These new antiviral molecules may have the potential to 
control and treat the avian influenza virus infected individuals. 
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Virus influenza burung (AIV) adalah antara penyebab utama penyakit dan kematian spesis 
burung di dunia. Ia merupakan agen penyebab kebanyakan penyakit berbahaya yang lazimnya 
dikenali sebagai selsema burung di kalangan ternakan burung. Virus ini adalah dari keluarga 
Orthomyxoviridae yang terdiri daripada dua genera, influenza A & B dan influenza C. 
Walaupun virus-virus influenza A burung biasanya tidak menjangkiti manusia, terdapat 
beberapa kes wabak dan jangkitan manusia telah dilaporkan. ‘Spanish flu’, suatu pandemik 
influenza pada tahun 1918 yang dimaklumi ramai, dikatakan telah mengorbankan lebih 50 juta 
orang. Sungguhpun langkah pengvaksinan merupakan strategi utama bagi pengawalan 
jangkitan, antivirus dalam bentuk dadah memainkan peranan penting dalam pengawalan 
penyakit dan penyebaran virus.  
 
Dua kelas dadah antivirus telah disyorkan bagi merawat jangkitan influenza. Mereka adalah 
terbitan dadah kelas adamantine (amantadine dan rimantadine) dan perencat neuraminidase 
(NAIs; zanamivir dan oseltamivir). Kadar kerintangan terhadap adamantine di Amerika Syarikat 
sahaja telah meningkat dari bawah paras 2% kepada nilai amaran iaitu 92.3% beberapa tahun 
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kebelakangan ini. Sekelompok virus dengan kadar keberkesanan terhadap NAIs telah diperolehi. 
Beberapa pemencilan influenza baru daripada pesakit jangkitan influenza H5N1 didapati 
mempamerkan kerintangan terhadap kedua-dua kelas dadah antivirus.  
 
Peningkatan kehadiran strain-strain virus influenza dengan daya kerintangan serta kesan 
sampingan yang ada menekankan keperluan kita untuk mengenalpasti dadah-dadah antivirus 
yang baru. Dalam usaha mengenalpasti dadah-dadah antivirus novel, ‘phage display library’ 
telah digunakan dalam kajian ini. Mereka telah di’biopanned’ ke atas virus influenza burung 
H9N2 yang telah ditulenkan. Selepas empat kitaran ‘biopanning’, empat peptida telah 
dipencilkan. Ketepatan ikatan mereka telah dipastikan menggunakan kaedah ‘phage-ELISA’ 
yang telah diubahsuai. Antara empat peptida tersebut, peptida yang membawa jujukan 
NDFRSKTC (P1) telah dipilih untuk analisis seterusnya kerana ia menunjukkan kadar kehadiran 
yang tinggi selepas kitaran keempat ‘panning’ di samping mempunyai ciri-ciri perencat yang 
baik. 
 
Kebolehan merencat secara in vitro oleh peptida-peptida dan ‘fusion phages’ telah dianalisa 
berdasarkan keupayaan faj atau molekul peptida untuk menyekat pembiakan virus di dalam sel 
MDCK sementara keupayaan merencat peptida oleh ‘fusion phage’ secara in ovo adalah 
menggunakan telur ayam berembrio berusia 9 hari. Keupayaan molekul antivirus untuk 
merencat aktiviti hemaglutinasi dan ‘neuraminidase’ NA juga telah dikaji masing-masing 
menggunakan ujian perencatan hemaglutinasi dan ujian perencatan ‘neuraminidase’ konservatif. 
Ujian-ujian tersebut berjaya menunjukkan kesan perencatan activiti HA tetapi gagal untuk 
merencat aktiviti ‘neuraminidase’ secara keseluruhannya.  
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‘Antibody-phage competition assay’ menunjukkan bahawa molekul peptida berkongsi beberapa 
epitop lazim pada protein permukaan virus sebagai tapak pengikatannya. Bagi mengkaji 
keupayaan pengikatan secara in vivo molekul-molekul tersebut dalam persekitaran sel, interaksi 
antara peptida dan glikoprotein permukaan virus telah dianalisa menggunakan sistem ‘yeast 
two-hybrid’. Kawasan hujung C pada protein HA didapati berupaya mengikat peptida tersebut 
sementara protein NA menunjukkan interaksi yang lemah terhadap peptida. Ini telah dipastikan 
lagi melalui eksperimen ‘co-immunoprecipitation’. 
 
Untuk memahami mekanisme dadah dengan lebih mendalan, efek dadah tersebut terhadap 
pelekatan dan penembusan virus kedalam sel his telah dikaji mnggunakan kaedah mikroskop 
fluoresen dan “cytometry”. Kajian ini menunjukkan bahawa peptide-peptida ini mengelakkan 
pelekatan virus kepada sel hos, sekaligus mengesahkan hasil kajian eksperimen perencatan 
hemaglutinasi. Lagipun, peptide-peptida tersebut telah didapati boleh merencat ekspresi gen 
awal.  
 
Namun demikian, mereka tak mempunyai sebarang efek bagi mengelakkkan kemasukkan 
molekul-molekul virus. Kesimpulannya, kajian ini telah mengenalpasti satu peptida antivirus 
novel yang berupaya merencat pembiakan AIV H9N2 secara in ovo dan in vitro, melalui 
pengikatan tapak hujung C pada protein HA. Peptida ini mengelakkan pelekatan virus pada sel 
hos, sekaligus mencegah penembusan serta ekspresi protein awal virus.  Molekul-molekul 
antivirus baru ini mungkin berpotensi untuk mengawal dan merawat pesakit jangkitan virus 
influenza burung. 
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CHAPTER 1 
 
INTRODUCTION 
 
Avian influenza (AI) is caused by avian influenza virus (AIV) which belongs to the 
family Orthomyxoviridae, genus Influenza A. It rapidly infects poultry as well as many 
species of birds. The viruses are classified into subtypes on the basis of antigenic 
differences in their surface glycoprotein hemagglutinin (HA/H) and neuraminidase 
(NA/N). To date, 16 HA subtypes (H1-H16) and 9 NA subtypes (N1-N9) have been 
recognised (Webster et al., 1992). AIV can also be categorised as high pathogenicity 
(HP) and low pathogenicity (LP) on the basis of the severity of clinical signs and 
mortality rates in experimentally inoculated chickens (Swayne et al., 2000). HPAI is in 
list A disease of the Office International des Epizooties (OIE; http:www.oie.int, 
Septermber 2008). 
 
AIVs occur naturally among birds. Wild birds worldwide carry the viruses in their 
intestines, but usually do not get sick from them. Domesticated birds may become 
infected with AIV through direct contact with infected waterfowl or other infected 
poultry, or through contact with contaminated surfaces (such as dirt or cages) or 
materials (such as water or feed) (Goldrick and Goetz, 2007). 
 
Infection with AIVs in domestic poultry causes two main forms of disease that are 
distinguished by low and high extremes of virulence. The “low pathogenic” form may 
